GlassScriptPhysician profile
Ellois W Bailey
NPI 1639432461
$3,221.91
in general payments reported to CMS, 2019-2025
18 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $604 · 2022: $638 · 2023: $759 · 2024: $722 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.04 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.89 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $532.12 | 2021-2025 | Rexulti, Abilify Mycite |
| Axsome Therapeutics, INC. | $332.75 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $300.52 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $218.64 | 2021-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $171.10 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $138.05 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $132.80 | 2021-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $124.88 | 2023-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $76.84 | 2022-2024 | Quviviq |
| Corium, LLC | $55.73 | 2022-2024 | Azstarys |
| Tris Pharma INC | $44.83 | 2022-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $39.20 | 2021 | |
| Supernus Pharmaceuticals, INC. | $30.98 | 2022-2023 | Qelbree |
| Alkermes, INC. | $27.19 | 2022-2023 | Lybalvi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $17.59 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.53 | 2025 | Cobenfy |
| Eisai INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellois Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.